Levodopa/Carbidopa/Entacapon Beta

Levodopa, the active ingredient in Levodopa/Carbidopa/Entacapone Beta, is an antiparkinson agent presented as an oral tablet for oral use. It is used to manage the motor symptoms of Parkinson's disease in adult patients. GNH USA supplies Levodopa/Carbidopa/Entacapone Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone acts within the dopaminergic pathway to treat Parkinson's disease and related motor complications. - Parkinson's disease: improves bradykinesia, rigidity and tremor. - Parkinson's disease with motor fluctuations: reduces OFF time and prolongs ON periods. - Early‑stage Parkinson's disease: helps delay the need for additional dopaminergic therapy.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually resolves. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements that may be disabling. - Hallucinations or psychosis: visual or auditory disturbances, especially in older patients. - Severe hypotension: marked drop in blood pressure leading to fainting.

Before initiating therapy, consider the following safety measures. - Monitor blood pressure: risk of orthostatic hypotension, especially at treatment start. - Assess psychiatric status: may precipitate hallucinations or confusion. - Adjust dose in renal impairment: use caution and monitor renal function. - Avoid abrupt discontinuation: sudden stop can worsen Parkinsonian symptoms. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levodopa/Carbidopa/Entacapone can interact with several drug classes.

Major Interactions (Avoid): - MAO‑B inhibitors: may cause hypertensive crisis. - Non‑selective MAO inhibitors: risk of severe hypertension. - Anticholinergics: can mask Parkinsonian symptoms. - Antihypertensives: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: monitor for serotonin syndrome. - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: may decrease levodopa efficacy; consider timing of intake.